Other3

BioStem Technologies, Inc.

Total Value

$NaN

Filing Date

Aug 14, 2026

1 transactions

Trade Summary

On Aug 6, 2026, Matuszewski Jason, Insider, reported $NaN of BioStem Technologies, Inc. (BSEM) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Matuszewski Jason
Role: Insider
Location: POMPANO BEACH, FL

Filing Details

Filing Date: Aug 14, 2026
Transaction Date: Aug 6, 2026
Accession Number: 0001634730-26-000004
Form Type: 3

Want live alerts when Matuszewski Jason trades again?

Download Insider Trades to track BSEM, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)These options are fully vested and exercisable.
(F2)These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
(F3)These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
(F4)These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
(F5)These restricted stock units vest in equal quarterly installments over 3 years from the grant date (September 15, 2024).
(F6)Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
(F7)These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
(F8)These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Matuszewski Jason

(Last)

(First)

(Middle)

C/O BIOSTEM TECHNOLOGIES, INC.

2836 CENTER PORT CIRCLE

(Street)

POMPANO BEACH

33064

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
BioStem Technologies, Inc. [ BSEM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,278,433	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	10/24/2032	Common Stock	2,250,000	$2	D
Stock Option (Right to Buy)	⁽²⁾	03/17/2035	Common Stock	198,807	$10.05	D
Stock Option (Right to Buy)	⁽³⁾	10/13/2035	Common Stock	40,427	$10.05	D
Stock Option (Right to Buy)	⁽⁴⁾	02/11/2036	Common Stock	440,529	$5.5	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock	42,343	⁽⁶⁾	D
Restricted Stock Units	⁽⁷⁾	⁽⁷⁾	Common Stock	116,550	⁽⁶⁾	D
Restricted Stock Units	⁽⁸⁾	⁽⁸⁾	Common Stock	363,636	⁽⁶⁾	D

Explanation of Responses:

1. These options are fully vested and exercisable.

2. These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

3. These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

4. These options vest according to the following schedule: 33% will vest on February 11, 2027, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.

5. These restricted stock units vest in equal quarterly installments over 3 years from the grant date (September 15, 2024).

6. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

7. These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

8. These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.

	/s/ Jason Matuszewski	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0001634730-26-000004.

BioStem Technologies, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when Matuszewski Jason trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3